NR1H4 and metabolic dysfunction-associated steatotic liver disease: FXR activation improves lipid metabolism and reduces liver inflammation, offering a new avenue for managing metabolic liver disorders.389–391 Obeticholic acid, an FXR agonist also known as INT-747, is approved for treating NAFLD and NASH392 [NCT02548351].